Evidence map›Paper›PMID 35847486›Full record

ReviewActa pharmaceutica Sinica. B2022

The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies.

Tiecheng Zhong, Wenxin Zhang, Hongjie Guo, Xiaohui Pan, Xi Chen, Qiaojun He, Bo Yang, Ling Ding

Open access · diamondAbstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Transient receptor potential channels inChannels (Austin, Tex.) · 2026
    Review
  4. Review
  5. Advances in applications of siRNA in cancer therapy: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tiecheng ZhongZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Wenxin ZhangZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Hongjie GuoZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Xiaohui PanZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Xi ChenZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Qiaojun HeZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Bo YangZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Ling DingZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transient receptor potential (TRP) channels are one primary type of calcium (Ca

Indexed as

4α-PDD, 4α-phorbol-12,13-didecanoateABCB, ATP-binding cassette B1AKT, protein kinase BALA, alpha lipoic acidAMPK, AMP-activated protein kinaseAPB, aminoethoxydiphenyl borateATP, adenosine triphosphateCancer progressionCaR, calcium-sensing receptorCaSR, calcium sensing receptorCBD, cannabidiolCRAC, Ca2+ release-activated Ca2+ channelDAG, diacylglycerolDBTRG, Denver Brain Tumor Research GroupECFC, endothelial colony-forming cellsECM, enhanced extracellular matrixEGF, epidermal growth factorEMT, epithelial–mesenchymal transitionER, endoplasmic reticulumERK, extracellular signal-regulated kinaseETS, erythroblastosis virus E26 oncogene homologFAK, focal adhesion kinaseGADD, growth arrest and DNA damage-inducible geneGC, gastric cancerGPCR, G-protein coupled receptorGSC, glioma stem-like cellsGSK, glycogen synthase kinaseHCC, hepatocellular carcinomaHIF, hypoxia-induced factorHSC, hematopoietic stem cellsIntracellular mechanismIP3R, inositol triphosphate receptorKO, knockoutLOX, lipoxygenaseLPS, lipopolysaccharideLRP, lipoprotein receptor-related proteinMAPK, mitogen-activated protein kinaseMLKL, mixed lineage kinase domain-like proteinMMP, matrix metalloproteinasesmTOR, mammalian target of rapamycinNEDD4, neural precursor cell expressed, developmentally down-regulated 4NFAT, nuclear factor of activated T-cellsNLRP3, NLR family pyrin domain containing 3NO, nitro oxideNrf2, nuclear factor erythroid 2-related factor 2NSCLC, non-small cell lung cancerPCa, prostate cancerPDAC, pancreatic ductal adenocarcinomapFRG/RTN, parafacial respiratory group/retrotrapezoid nucleusP-gp, P-glycoproteinPHD, prolyl hydroxylasesPI3K, phosphoinositide 3-kinasePKC, protein kinase CPKD, polycystic kidney diseasePLC, phospholipase CProgrammed cancer cell deathRNS/ROS, reactive nitrogen species/reactive oxygen speciesRTX, resiniferatoxinSMAD, Caenorhabditis elegans protein (Sma) and mothers against decapentaplegic (Mad)SOCE, store operated calcium entrySOR, soricimedSTIM1, stromal interaction molecules 1Targeted tumor therapyTEC, tumor endothelial cellsTGF, transforming growth factor-βTNF-α, tumor necrosis factor-αTRPA/C/M/ML/N/P/V, transient receptor potential ankyrin/canonical/melastatin/mucolipon/NOMPC/polycystin/vanilloidTRP channelsTumor-associated immunocytesTumor microenvironmentUPR, unfolded protein responseVEGF, vascular endothelial growth factorVIP, vasoactive intestinal peptideVPAC, vasoactive intestinal peptide receptor subtype

Identifiers

PMID35847486
PMCPMC9279634
OpenAlexW3213809578

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.